MUMBAI, India, June 26 Lupin Ltd, announced today that Dr.Raj Kamboj has joined the company as President -- New Chemical EntityResearch. This reflects the Company's commitment to continually strengthen itsteam by attracting the best talent globally.
Raj is an eminent scientist from the world of drug discovery. He is a PhDfrom University of Adelaide, Australia & joins Lupin from XenonPharmaceuticals Inc., Vancouver, where he had been working for the past 5years. He has returned to India after 26 years and brings with him a widerange of experience in the field of Drug Discovery & Clinical development.Prior to Xenon, he was working with Allelix, Canada. In both companies Raj wasinstrumental in taking the companies from the inception of the drug discoverygroup all the way to multiple licensing transactions and collaborations.
"We are very excited to have Raj join us as the Chief of our drugdiscovery program," Dr. D B Gupta, Chairman, Lupin Ltd. said. "He brings withhim a vast pool of knowledge and experience which will be a great value addfor Lupin's NCE research."
Lupin is committed to developing new and innovative healthcare productsfocusing on unmet needs. It has a pipeline of four Investigational New Drugsthat focus on three different disease areas namely Migraine, Psoriasis andTuberculosis. The Company also has pre-clinical programs in Diabetes andRheumatoid Arthritis.
Headquartered in Mumbai, India, Lupin Limited is an innovation ledtransnational pharmaceutical company producing a wide range of quality,affordable generic and branded formulations and APIs for the developed anddeveloping markets of the world.
The Company has secured global leadership position in Anti-TB andCephalosporins and has a significant presence in the areas of Cardio-vasculars(prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&Dendeavors have resulted in significant progress in its NCE program. TheCompany's foray into Advanced Drug Delivery Systems has resulted in thedevelopment of platform technologies that are being used to developvalue-added generic pharmaceuticals.
Currently positioned amongst the top six pharmaceutical companies ofIndia, the Company is committed to achieve sustainable earnings and growth forall its stakeholders.
For the financial year ended March 2008, the Lupin's Revenues and Profitafter Tax were Rs.27, 730 million (US$ 694 million) and Rs.4,083 million(US$ 102 million) respectively.For further information please contact: Lupin Limited: Seema Ahuja Head, Corporate Communications Ph: 9920042046 Email: email@example.com OR Source Strategic Communications Pvt. Ltd. Archana Pradhan Ph: 9820330505 Email: firstname.lastname@example.org
SOURCE Lupin Ltd